文献速递血液净化与透析

艾考糊精与葡萄糖透析液用于腹膜透析每日一次长留腹:系统综述与荟萃分析

Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · Am J Kidney Dis · 2020-02-04

该系统综述纳入19项随机对照试验共1693例接受腹膜透析的肾衰竭患者,比较每日一次长留腹艾考糊精与纯葡萄糖透析液。艾考糊精改善超滤(中期MD 208.92 mL/24h)并减少液体超负荷事件(RR 0.43),可能降低死亡风险(Peto OR 0.49),但未显著改变空腹血糖和HbA1c,安全性及残余肾功能两组相似。

要点

  • 艾考糊精每日一次长留腹可改善超滤并减少液体超负荷事件。
  • 含艾考糊精方案可能降低死亡风险,但证据确定性中等且事件数少。
  • 艾考糊精未显著改善空腹血糖或HbA1c,安全性与残余肾功能相似。

核心结论

  • 每日一次长留腹使用艾考糊精对部分腹膜透析患者有临床获益,包括未达超滤目标和有液体超负荷风险者。
  • 未来需开展以患者为中心结局和成本效果的研究。

研究设计与样本

  • 系统综述与荟萃分析,纳入19项随机对照试验共1693例接受规律腹膜透析的肾衰竭患者。

主要发现

  • 艾考糊精改善超滤:中期平均差208.92 mL/24h(95%CI 99.69-318.14),证据确定性高。
  • 艾考糊精减少液体超负荷事件:RR 0.43(95%CI 0.24-0.78),证据确定性高。
  • 含艾考糊精腹膜透析可能降低死亡风险:Peto OR 0.49(95%CI 0.24-1.00),证据确定性中等。
  • 含艾考糊精腹膜透析降低腹膜葡萄糖吸收:中期平均差-40.84 g/长留腹(95%CI -48.09至-33.59),证据确定性高。
  • 空腹血糖变化-0.50 mmol/L(95%CI -1.19至0.18,证据确定性低),HbA1c变化-0.14%(95%CI -0.34%至0.05%,证据确定性高),均无显著差异。

关键数值与推荐

  • 超滤中期平均差208.92 mL/24h(95%CI 99.69-318.14)。
  • 液体超负荷事件RR 0.43(95%CI 0.24-0.78)。
  • 死亡风险Peto OR 0.49(95%CI 0.24-1.00)。
  • 腹膜葡萄糖吸收中期平均差-40.84 g/长留腹(95%CI -48.09至-33.59)。
  • 空腹血糖平均差-0.50 mmol/L(95%CI -1.19至0.18),HbA1c平均差-0.14%(95%CI -0.34%至0.05%)。

临床怎么用

  • 对于未达超滤目标或有液体超负荷风险的腹膜透析患者,可考虑每日一次长留腹使用艾考糊精。
  • 艾考糊精对血糖控制的影响不显著,不能替代降糖治疗。
  • 需结合患者残余肾功能、容量状态及成本等因素个体化选择透析液。

局限性

  • 纳入试验质量参差不齐。
  • 随访期异质,缺乏长期评估。
  • 死亡结局仅基于32个事件,且未通过个体患者数据的时依分析证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The efficacy and safety of icodextrin versus glucose-only peritoneal dialysis (PD) regimens is unclear. The aim of this study was to compare once-daily long-dwell icodextrin versus glucose among patients with kidney failure undergoing PD. STUDY DESIGN: Systematic review of randomized controlled trials (RCTs), enriched with unpublished data from investigator-initiated and industry-sponsored studies. SETTING & STUDY POPULATIONS: Individuals with kidney failure receiving regular PD treatment enrolled in clinical trials of dialysate composition. SELECTION CRITERIA FOR STUDIES: Medline, Embase, CENTRAL, Ichushi Web, 10 Chinese databases, clinical trials registries, conference proceedings, and citation lists from inception to November 2018. Further data were obtained from principal investigators and industry clinical study reports. DATA EXTRACTION: 2 independent reviewers selected studies and extracted data using a prespecified extraction instrument. ANALYTIC APPROACH: Qualitative synthesis of demographics, measurement scales, and outcomes. Quantitative synthesis with Mantel-Haenszel risk ratios (RRs), Peto odds ratios (ORs), or (standardized) mean differences (MDs). Risk of bias of included studies at the outcome level was assessed using the Cochrane risk-of-bias tool for RCTs. RESULTS: 19 RCTs that enrolled 1,693 participants were meta-analyzed. Ultrafiltration was improved with icodextrin (medium-term MD, 208.92 [95% CI, 99.69-318.14] mL/24h; high certainty of evidence), reflected also by fewer episodes of fluid overload (RR, 0.43 [95% CI, 0.24-0.78]; high certainty). Icodextrin-containing PD probably decreased mortality risk compared to glucose-only PD (Peto OR, 0.49 [95% CI, 0.24-1.00]; moderate certainty). Despite evidence of lower peritoneal glucose absorption with icodextrin-containing PD (medium-term MD, -40.84 [95% CI, -48.09 to-33.59] g/long dwell; high certainty), this did not directly translate to changes in fasting plasma glucose (-0.50 [95% CI, -1.19 to 0.18] mmol/L; low certainty) and hemoglobin A1c levels (-0.14% [95% CI, -0.34% to 0.05%]; high certainty). Safety outcomes and residual kidney function were similar in both groups; health-related quality-of-life and pain scores were inconclusive. LIMITATIONS: Trial quality was variable. The follow-up period was heterogeneous, with a paucity of assessments over the long term. Mortality results are based on just 32 events and were not corroborated using time-to-event analysis of individual patient data. CONCLUSIONS: Icodextrin for once-daily long-dwell PD has clinical benefit for some patients, including those not meeting ultrafiltration targets and at risk for fluid overload. Future research into patient-centered outcomes and cost-effectiveness associated with icodextrin is needed.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Goossen K, Becker M, Marshall MR, et al. Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Kidney Dis. 2020. PMID: 32033860. doi:10.1053/j.ajkd.2019.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。